Vascular outcomes in patients with screen-detected or clinically diagnosed type 2 diabetes: Diabscreen study follow-up

Annals of Family Medicine

Volumn 11, Issue 1, 2013, Pages 20-27

  Klein Woolthuis, Erwin P ^a   de Grauw, Wim J C ^a   van Keeken, Susanne M ^a   Akkermans, Reinier P ^a   van de Lisdonk, Eloy H ^a   Metsemakers, Job F M ^b   van Weel, Chris ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Cardiovascular; Chronic care: comorbidity multimorbidity; Diagnostic testing; Endocrinology: diabetes; Practice based research

Indexed keywords

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETIC ANGIOPATHY; FEMALE; FOLLOW UP; GENERAL PRACTICE; HEART INFARCTION; HUMAN; MALE; MASS SCREENING; MIDDLE AGED; MORTALITY; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK; TREATMENT OUTCOME;

AGED; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FAMILY PRACTICE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MYOCARDIAL INFARCTION; NETHERLANDS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK; STROKE;

MLCS; MLOWN;

EID: 84872349099     PISSN: 15441709     EISSN: 15441717     Source Type: Journal    
DOI: 10.1370/afm.1460     Document Type: Article

References (22)

1. American Diabetes Association. Standards of medical care in diabe-tes-2012. Diabetes Care. 2012;35(Suppl 1):S11-S63.
2. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care. 1992;15(7):815-819.
3. Sarwar N, Gao P, Seshasai SR, et al. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-2222. Correction in Lancet. 2010;376(9745):958.
4. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-1053.
5. Hogan P, Dall T, Nikolov P; American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003; 26(3):917-932.
6. Norris SL, Kansagara D, Bougatsos C, Fu R; U.S. Preventive Services Task Force. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;148(11):855-868.
7. Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med. 2009;151(6):394-403.
8. Klein Woolthuis EP, de Grauw WJ, van Gerwen WH, et al. Yield of opportunistic targeted screening for type 2 diabetes in primary care: the Diabscreen study. Ann Fam Med. 2009;7(5):422-430.
9. Bouma M, Rutten GE, de Grauw WJ, Wiersma T, Goudswaard AN. Nederlands Huisartsen Genootschap. [Summary of the practice guideline 'Diabetes mellitus type 2' (2nd revision) from the Dutch College of General Practitioners]. Ned Tijdschr Geneeskd. 2006;150(41):2251-2256. Original guidelines in Dutch: http://nhg.artsennet.nl/kenniscentrum/k_richtlijnen/k_nhgstandaarden/Samenvattingskaartje-NHGStandaard/M01_svk.htm.
10. de Grauw WJ, van Gerwen WH, van de Lisdonk EH, van den Hoogen HJ, van den Bosch WJ, van Weel C. Outcomes of audit-enhanced monitoring of patients with type 2 diabetes. J Fam Pract. 2002;51(5):459-464.
11. Van Weel C. The Continuous Morbidity Registration Nijmegen: background and history of a Dutch general practice database. Eur J Gen Pract. 2008;14(Suppl 1):5-12.
12. Klein Woolthuis EP, de Grauw WJ, van Gerwen WH, et al. Identifying people at risk for undiagnosed type 2 diabetes using the GP's electronic medical record. Fam Pract. 2007;24(3):230-236.
13. The Expert Committee on the Diagnosis and Classif cation of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classif cation of Diabetes Mellitus. Diabetes Care. 1997; 20(7):1183-1197.
14. Levey AS, Bosch J P, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130(6):461-470.
15. Spijkerman AM, Dekker JM, Nijpels G, et al. Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the Hoorn Screening Study. Diabetes Care. 2003;26(9):2604-2608.
16. Spijkerman AMW, Henry RMA, Dekker JM, et al. Prevalence of macrovascular disease amongst type 2 diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the Hoorn Screening Study. J Intern Med. 2004;256(5): 429-436.
17. Fleming DM, Schellevis FG, Van Casteren V. The prevalence of known diabetes in eight European countries. Eur J Public Health. 2004;14(1):10-14.
18. World Health Organization. Screening for Type 2 diabetes. Report of a World Health Organization and International Diabetes Federation meeting. 2003. Geneva, Switzerland, World Health Organization. http://www.who.int/diabetes/publications/en/. Accessed Mar 3, 2012.
19. Engelgau MM, Narayan KM, Herman WH. Screening for type 2 diabetes. Diabetes Care. 2000;23(10):1563-1580.
20. Genuth S, Alberti KG, Bennett P, et al. Expert Committee on the Diagnosis and Classif cation of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26(11): 3160-3167.
21. de Grauw WJ, van de Lisdonk EH, van den Hoogen HJ, van Weel C. Cardiovascular morbidity and mortality in type 2 diabetic patients: a 22-year historical cohort study in Dutch general practice. Diabet Med. 1995;12(2):117-122.
22. Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia. 2011;54(1):25-31.